60 research outputs found

    Recovering Parody in Teaching Poetry Online

    Get PDF
    A survey of English verse parodies since the Renaissance, undertaken in teaching an online poetry course, allows us to see the form less as irreverent burlesque than as a reworking, openly or indirectly, of another poem and its subject. Although parodies act as touchstones for poems which a reading community judges excellent, they can critique or mock a text. Modernist poets, subversively extending the form of parody itself, also use it entirely to rebuild the subject of the original so as to serve a contemporary audience. Jon Stallworthy’s “My Last Mistress” and Alicia Ostriker’s “Holocaust” exemplify this type. They write what I term the reconstructive parody.Un estudio sobre las parodias inglesas escritas en verso desde el Renacimiento, tal como hemos acometido en la enseñanza de un curso de poesĂ­a en lĂ­nea, hace que no las aprecie- mos tanto como una forma irreverente burlesca sino mĂĄs bien como una reelaboraciĂłn —abierta o indirectamente— de otro poema y del tema que trata. Aunque las parodias aparecen como piedras de toque de poemas, que una determinada comunidad de lectores considera excelentes, las parodias pueden ejercer una crĂ­tica o burlarse de un texto. Al am- pliar la forma de la parodia e introducir un tono subversivo, los poetas modernistas tambiĂ©n la utilizaron para reconstruir el tema del original y para que sirviera a los lectores de su Ă©poca. “My Last Mistress” de Jon Stallworthy y “Holocaust” de Alicia Ostriker ejemplifican este tipo de parodias. Estos dos poetas escriben lo que yo denomino parodia reconstructiva

    Practising Place – Inhabiting the Landscape: Art, Archaeology and the Performance of Place

    Get PDF
    Practising Place is a programme of public conversations, designed to examine the relationship between art practice and place. Each event is hosted at a different venue in the North of England and explores a specific aspect of place by bringing artists together with people from different backgrounds, who share a common area of interest. Inhabiting the Landscape explored ways of understanding the landscape through an immersive engagement with it. Drawing on their respective practices of art and landscape archaeology, the speakers (Ian Nesbitt & Ruth Levene in conversation with Bob Johnston) discussed the idea of landscape as the product of human actions, with a focus on traditions of land use, boundaries and authoritative and unofficial forms of mapping. In particular, they examined how activities such as walking and oral history can generate alternative perspectives of landscape, which challenge established narratives and reveal the shifting meanings of a place

    The Expanded City - Stage One

    Get PDF
    The Expanded City is a three-stage project, which investigates the changing nature of cities. During the last decade, urban development was largely concerned with transforming post-industrial city centres into retail and residential developments. However, projects such as Preston’s City Deal scheme – part of a national initiative to encourage economic growth in key cities across England – increasingly involve building cities from the outside in. For 10 years In Certain Places has focused on and shaped developments within the city centre of Preston. The Expanded City extends the methods and approaches refined over the last decade to new contexts and locations; the city’s edges. What are the contributions artists can make to the external perceptions and internal experiences of inner city and suburban places? How can that inform debate about the imminent future of these places in terms of urban planning and cultural provision? Following an invitation by Preston City Council, In Certain Places has been working with commissioned artists Olivia Keith, Gavin Renshaw, Emily Speed and duo Ian Nesbitt and Ruth Levene, and The Decorators. The artists have investigated the physical and cultural topography of the outskirts of Preston, ‘deep mapping’ the areas marked for growth. Through a focus on the practical and political aspects of issues such as housing, play and leisure provision, transport infrastructure, emotional connections to the land, and environmental stewardship, the artists have developed projects which raise questions about and offer suggestions for the future of Preston and other expanding cities. All the artists share an interest in boundaries, routes, edges and the urban/rural binary, and work across a range of media, including film, photography and performance. The commissions will explore the social and physical aspects of the places, their relationships with the city centre and the potential implications of planned developments. Writer and curator Lauren Velvick contextualised and provided a critical narrative for the development of the work of the artists in a regular Expanded City blog. Stage one beginning in 2016 saw the beginning of research and development. The work of this first phase is summarised in the 2016 publication produced by Lauren Velvick, the project's ‘writer in residence’. The publication contextualised and provided a critical narrative for the development of the artists’ work. This phase also saw the Expanded City Symposium. The symposium which took place in Woodplumpton and District Club in the north of Preston, presented the first stage of research in the Expanded City project. Alongside presentations about urban demographics by economist Paul Swinney, the production of community spaces by design collective The Decorators, and a performance lecture by Ian Nesbitt and Ruth Levene, the day included a bus trip around the City Deal areas, where Gavin Renshaw, Olivia Keith and Lauren Velvick presented their work-in-progress

    SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis

    Get PDF
    Background: Although the use of proliferation markers/profiles has been recommended when choosing the appropriate systemic-treatment for breast cancer (BC), the best molecular-marker/test that should be used needs to be identified. Methods: To identify factors that drive proliferation and its associated features in BC an artificial neural network (ANN) based integrative data-mining methodology was applied to three cohorts [(Nottingham-discovery (ND), Uppsala and METABRIC (Molecular Taxonomy of Breast Cancer International Consortium)]. The most prominent genes in the resulting interactome-map were then identified. Given that SPAG5 was associated with many features of proliferation, featured prominently in the interactome-map and has a fundamental role in mitotic-progression,, we hypothesized that it could be a better indicator of proliferation activity. (BC). Subsequently to test if it could provide a more accurate guide for the delivery of systemic therapies in BC, we investigated the clinico-pathological utility of SPAG5: gene copy number aberrations (CNAs); mRNA and protein expression, in over 10,000 BCs. Integrated analysis of SPAG5-gene CNAs, transcript and protein expression was conducted in the ND cohort (n=171) and validated in the METABRIC cohort (n=1980). In addition, the associations of SPAG5 CNAs, transcript and/or protein with BC specific survival (BCSS), disease free survival (DFS) and/or distant relapse free survival (DRFS) were analysed in multiple cohorts including Uppsala (n=249), METABRIC, three-untreated lymph node (LN) negative cohorts (n=684), a combined multicentre clinical data set (n=5439), Nottingham historical early-stage-primary BC (Nottingham-HES-BC; n=1650), Nottingham oestrogen receptor (ER) negative BC (n=697), Nottingham anthracycline-Neoadjuvant-chemotherapy (Nottingham-AC-Neo-ACT; n=200), and MD Anderson Cancer Centre Taxane/anthracycline (MDACC-T/AC-Neo-ACT; n=508) cohorts. The association of SPAG5 transcript and protein expression with pathological response rate (pCR) were also tested in [MDACC-T/AC-Neo-ACT (n=508) and the phase II trial NCT00455533; n=253)] and [Nottingham-AC-Neo-ACT (n=200)] cohorts; respectively. Findings: SPAG5 gene gain/amplification at the Ch17q11·2 locus was found in 10.4% of BC (206/1980 (; METABRIC) and was reported in 19·4% of PAM50-HER2 (46/237) and 17·8% of PAM50-LumB (87/488). SPAG5-CNA gain/amplification and high SPAG5-transcript and SPAG5-protein were associated with increased risk of death from BC [Uppsala; (HR (CI 95%): 1·50 (1·18-1·92); p=0·00010, METABRIC; (HR (CI 95%): 1·68 (1·40-2·01) p<0·0001), and Nottingham-HSE-BC; (HR (CI 95%): 1·68 (1·32-2·12), p<0·0001); respectively]. Multivariable Cox regression models, including other validated-prognostic factors, (Uppsala: age, size, LN-stage, genomic grade index (GGI), ER, TP53 mutation and MKi67; METABRIC: age, size, LN-stage, histologic-grade, ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), hormone-therapy, chemotherapy, interaction term of SPAG5 and both chemotherapyy and hormonotherapy; Desmedt-untreated LN- cohort: ER, Nottingham prognostic index (NPI), 76-gene prognostic signature (Veridex) and Adjuvant-Online (AOL); Nottingham-HES-BC: menopausal status, size, LN- stage, histologic-grade, ER, PR, HER2, ki67, hormone-therapy, chemotherapy, interaction term of SPAG5 and both chemotherapy[y and hormonotherapy), showed that high SPAG5-transcript and high SPAG5-protein were associated with shorter BCSS [Uppsala: (HR (CI 95%): 1·62 (1·03-2·53) p=0·036); METABRIC: (HR (CI 95%): 1·27 (1·02-1·58) p=0·034); Desmedt-untreated LN- cohort: (HR (CI 95%): 2·34 (1·24-4·42) p=0·0090), and Nottingham-HES-BC (HR (CI 95%): 1·73 (1·23-2·46) p=0·0020); respectively]. In ER-negative-BC with high SPAG5-protein, administration of anthracycline-adjuvant-chemotherapy had reduced the risk of death by 60% compared to chemotherapy-naive (HR (95% CI): 0·37 (0·20-0·60); p=0·0010). A multivariable Cox regression analysis, which included other validated prognostic factors for chemotherapy (e.g., menopausal status, size, lymph node stage, histologic grade, ER, PR, HER2, Bcl2, chemotherapy, interaction term of SPAG5 and both chemotherapy[y), revealed that SPAG5-transcript+ was independently associated with decreased risk of DRFS after receiving Taxane/anthracycline-Neo-ACT [MDACC-T/AC-Neo-ACT: (HR (CI 95%): 0·68 (0·48-0·97); p=0·0070)]. In multivariable logistic regression analysis, both SPAG5-transcript+ and SPAG5-protein+ and were independent predictors for higher pCR after combination-cytotoxic chemotherapy [MDACC-T/AC-Neo-ACT: (OR (95% CI) 1·71 (1·07-2·74); p=0·024), and Nottingham-AC-Neo-AC: (OR (95% CI): 8·75 (2·42-31); p=0·0010); respectively]. Interpretation: SPAG5 is a novel amplified gene on Ch17q11.2 in PAM50-LumB and PAM-HER2 BC, and its transcript and protein products are independent prognostic and predictive biomarkers, with potential clinical utility as a biomarker for combination cytotoxic chemotherapy sensitivity, especially in ER- BC

    The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes

    Get PDF
    Background: Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity and patient outcome. This study aimed to evaluate the biological and prognostic value of the membrane solute carrier, SLC3A2 in BC with emphasis on the intrinsic molecular subtypes. Methods: SLC3A2 was assessed at the genomic level, using METABRIC data (n=1,980), and proteomic level, using immunohistochemistry on TMA sections constructed from a large well-characterised primary BC cohort (n=2,500). SLC3A2 expression was correlated with clinicopathological parameters, molecular subtypes, and patient outcome. Results: SLC3A2 mRNA and protein expression were strongly correlated with higher tumour grade and poor Nottingham prognostic index (NPI). High expression of SLC3A2 was observed in triple negative (TN), HER2+, and ER+ high proliferation subtypes. SLC3A2 mRNA and protein expression were significantly associated with the expression of c-MYC in all BC subtypes (p<0.001). High expression of SLC3A2 protein was associated with poor patient outcome (p<0.001)), but only in the ER+ high proliferation (p=0.01) and triple negative (p=0.04) subtypes. In multivariate analysis SLC3A2 protein was an independent risk factor for shorter breast cancer specific survival (p<0.001). Conclusions: SLC3A2 appears to play a role in the aggressive BC subtypes driven by MYC and could act as a potential prognostic marker. Functional assessment is necessary to reveal its potential therapeutic value in the different BC subtypes

    MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

    Get PDF
    BACKGROUND: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We hypothesised that the functional role of c-MYC differs between molecular subtypes of BCs. METHODS: We therefore investigated the correlation between c-MYC protein expression and other proteins involved in different cellular functions together with clinicopathological parameters, patients' outcome and treatments in a large early-stage molecularly characterised series of primary invasive BCs (n=1106) using immunohistochemistry. The METABRIC BC cohort (n=1980) was evaluated for MYC mRNA expression and a systems biology approach utilised to identify genes associated with MYC in the different BC molecular subtypes. RESULTS: High MYC and c-MYC expression was significantly associated with poor prognostic factors, including grade and basal-like BCs. In luminal A tumours, c-MYC was associated with ATM (P=0.005), Cyclin B1 (P=0.002), PIK3CA (P=0.009) and Ki67 (P<0.001). In contrast, in basal-like tumours, c-MYC showed positive association with Cyclin E (P=0.003) and p16 (P=0.042) expression only. c-MYC was an independent predictor of a shorter distant metastases-free survival in luminal A LN+ tumours treated with endocrine therapy (ET; P=0.013). In luminal tumours treated with ET, MYC mRNA expression was associated with BC-specific survival (P=0.001). In ER-positive tumours, MYC was associated with expression of translational genes while in ER-negative tumours it was associated with upregulation of glucose metabolism genes. CONCLUSIONS: c-MYC function is associated with specific molecular subtypes of BCs and its overexpression confers resistance to ET. The diverse mechanisms of c-MYC function in the different molecular classes of BCs warrants further investigation particularly as potential therapeutic targets

    Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans

    Get PDF
    Genome-wide association studies (GWAS) have identified numerous common prostate cancer (PrCa) susceptibility loci. We have fine-mapped 64 GWAS regions known at the conclusion of the iCOGS study using large-scale genotyping and imputation in 25 723 PrCa cases and 26 274 controls of European ancestry. We detected evidence for multiple independent signals at 16 regions, 12 of which contained additional newly identified significant associations. A single signal comprising a spectrum of correlated variation was observed at 39 regions; 35 of which are now described by a novel more significantly associated lead SNP, while the originally reported variant remained as the lead SNP only in 4 regions. We also confirmed two association signals in Europeans that had been previously reported only in East-Asian GWAS. Based on statistical evidence and linkage disequilibrium (LD) structure, we have curated and narrowed down the list of the most likely candidate causal variants for each region. Functional annotation using data from ENCODE filtered for PrCa cell lines and eQTL analysis demonstrated significant enrichment for overlap with bio-features within this set. By incorporating the novel risk variants identified here alongside the refined data for existing association signals, we estimate that these loci now explain ∌38.9% of the familial relative risk of PrCa, an 8.9% improvement over the previously reported GWAS tag SNPs. This suggests that a significant fraction of the heritability of PrCa may have been hidden during the discovery phase of GWAS, in particular due to the presence of multiple independent signals within the same regio

    Combinatorial biomarker expression in breast cancer

    Full text link
    • 

    corecore